Tuesday, March 10, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Consumer & Luxury

Altria Executives Report Share Transactions Under Pre-Arranged Plans

SiterGedge by SiterGedge
March 10, 2026
in Consumer & Luxury, Insider Trading
0
Altria Stock
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

Two senior executives at tobacco giant Altria Group Inc. have recently reported changes to their equity holdings, with both transactions characterized as routine. The moves were executed under predetermined trading plans, a mechanism designed to prevent insider trading by scheduling transactions in advance, thereby negating any suggestion they were based on material non-public information.

Details of the Executive Trades

The first transaction involved Charles N. Whitaker, who serves as the company’s Chief Human Resources Officer and Chief Compliance Officer. On March 5, 2026, Whitaker sold a total of 27,908 shares at an average price of $67.57 per share. This sale generated proceeds of approximately $1.89 million. Following this divestment, his direct holdings stand at 180,869 shares. This total includes 60,552 restricted stock units. Additionally, he holds an indirect interest in 1,017 more shares through the company’s Deferred Profit-Sharing Plan.

In a separate filing from early March, Robert A. McCarter III, Altria’s Executive Vice President and General Counsel, reported a change in his position. He received 5,767 shares following the vesting of performance stock units. Concurrently, and as is standard practice, he surrendered 4,517 of those shares to cover associated tax liabilities—a non-discretionary, automated procedure. After these adjustments, McCarter’s direct share ownership totals 123,612 shares.

Should investors sell immediately? Or is it worth buying Altria?

Strategic Focus and Financial Guidance Remain Unchanged

These insider transactions occur as the company continues to execute its long-term operational strategy. During the Consumer Analyst Group of New York Conference in February 2026, management reaffirmed its full-year outlook. For the 2026 fiscal year, Altria anticipates adjusted diluted earnings per share (EPS) to land in the range of $5.56 to $5.72, with the pace of growth expected to accelerate in the latter half of the year. This forecast follows a reported fourth-quarter 2025 EPS of $1.30.

The company continues to pay a regular quarterly dividend of $1.06 per share. Strategically, Altria is focused on gradually building a portfolio of smoke-free products, an initiative funded by the cash flows from its core traditional tobacco business.

Ad

Altria Stock: Buy or Sell?! New Altria Analysis from March 10 delivers the answer:

The latest Altria figures speak for themselves: Urgent action needed for Altria investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 10.

Altria: Buy or sell? Read more here...

Tags: Altria
SiterGedge

SiterGedge

Related Posts

Energy Fuels Stock
Commodities

Leadership Transition and Strategic Shifts at Energy Fuels

March 9, 2026
Samsung Electronics Stock
Asian Markets

Samsung Electronics Strengthens Grip on Global Television Market

March 9, 2026
Take-Two Stock
Analysis

A Pivotal Week for Take-Two Interactive Amid Key Launches and Insider Moves

March 9, 2026
Next Post
Boeing Stock

Boeing Shares Surge on Prospect of Major China Order

Johnson & Johnson Stock

Johnson & Johnson's Oncology Pipeline Gains Momentum with Dual Drug Approvals

Applied Digital Stock

Applied Digital Secures Major Funding for AI Infrastructure Push

Recommended

Marvell Technology Stock

Marvell Technology’s AI Ambitions Face Market Scrutiny After Mixed Results

6 months ago
Neurotechnology

Analyst Maria Ripps Reaffirms Hold Rating for Viant Technology with Increased Price Target

2 years ago
Applovin Stock

AppLovin’s Strategic Shift Garners Wall Street Confidence

5 months ago
Apex Critical Metals Stock

Apex Critical Metals Secures Major Funding Amid Critical Minerals Surge

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Axon Enterprise Shares Surge on Robust Quarterly Performance and Institutional Backing

CSG Systems Nears Final Chapter as Shareholders Back NEC Acquisition

Denali Therapeutics: Assessing the Drivers Behind Its Clinical Ambitions

AGNC Investment: A Monthly Dividend Strategy in Focus

Enovix Shares Face Investor Skepticism Despite Strong Quarterly Sales

Applied Digital Secures Major Funding for AI Infrastructure Push

Trending

Intuit Stock
Analysis

Intuit Stock Analysis: Can Recent Gains Signal a Lasting Recovery?

by Jackson Burston
March 10, 2026
0

Despite posting quarterly results that smashed Wall Street's forecasts, Intuit finds itself navigating a complex landscape marked...

Ampio Pharmaceuticals Stock

Ampio Pharmaceuticals: Final Steps in Corporate Wind-Down

March 10, 2026
Lumentum Stock

Lumentum Secures Dual Catalysts for Future Growth

March 10, 2026
Axon Enterprise Stock

Axon Enterprise Shares Surge on Robust Quarterly Performance and Institutional Backing

March 10, 2026
CSG Stock

CSG Systems Nears Final Chapter as Shareholders Back NEC Acquisition

March 10, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Intuit Stock Analysis: Can Recent Gains Signal a Lasting Recovery?
  • Ampio Pharmaceuticals: Final Steps in Corporate Wind-Down
  • Lumentum Secures Dual Catalysts for Future Growth

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com